Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category.

Athira Pharma, Inc. faces significant business risk due to its dependency on compliance with FDA regulations for its manufacturing processes. Any failure to adhere to these cGMP regulations could result in substantial delays or even termination of clinical programs, as well as suspension or withdrawal of regulatory approvals. The company may struggle with quality control and assurance, and potential shortages in qualified personnel could exacerbate these challenges. Non-compliance could lead to severe sanctions and damage to the company’s reputation, ultimately impacting its ability to develop and market its drug candidates effectively.

The average ATHA stock price target is $0.58, implying -12.11% downside potential.

To learn more about Athira Pharma, Inc.’s risk factors, click here.